Literature DB >> 12712357

Quality of life in patients with malignant choroidal melanoma after radiotherapy.

Jens Reimer1, Joachim Esser, Anja Fleiss, Aike Hessel, Gerasimos Anastassiou, Michael Krausz, Norbert Bornfeld, Gabriele Helga Franke.   

Abstract

BACKGROUND: Patient-orientated endpoints have attracted little attention in patients with malignant choroidal melanoma. This study was conducted to explore the long-term effects of malignant choroidal melanoma and radiotherapy on QOL by means of a differentiated and modular QOL approach, including global QOL, social support, and mental health, in comparison with sociodemographically matched healthy controls.
METHODS: A random sample of 100 outpatients treated by radiotherapy were asked by mail to take part in a psychodiagnostic study [instruments: Short-Form 36 Health-Survey (SF-36), Symptom Checklist-90-Revised, German Social Support Questionnaire]. The same instruments were applied to a healthy control group, which was matched to patients with regard to age, gender, and vocational situation.
RESULTS: 93 patients (average age 61.2 years) responded at an average of 5.5 years (+/-3.7) after diagnosis. Visual acuity in the affected eye decreased considerably from diagnosis (0.49+/-0.30) to participation in the study (0.09+/-0.21). Compared with healthy controls, patients reported on average statistically significantly lower global QOL (SF-36), whereas social support and mental distress did not differ. Frequencies of clinically relevant mental distress were significantly higher in patients than in controls (35.5% vs. 16.1%). Mental distress was associated with poorer visual acuity, but not with the extent of loss of visual acuity or number of follow-up treatments.
CONCLUSION: Patients with choroidal melanoma suffer from low long-term global QOL, and every third patient suffers from relevant mental distress. Regular screening for mental distress should be implemented along with psychological counseling. Additional follow-up treatment does not seem to induce mental distress.

Entities:  

Mesh:

Year:  2003        PMID: 12712357     DOI: 10.1007/s00417-003-0654-4

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  31 in total

1.  The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18.

Authors:  M Diener-West; J D Earle; S L Fine; B S Hawkins; C S Moy; S M Reynolds; A P Schachat; B R Straatsma
Journal:  Arch Ophthalmol       Date:  2001-07

2.  Questionnaire-based survey on the importance of quality of life measures in ophthalmic practice.

Authors:  P M Hart; U Chakravarthy; M R Stevenson
Journal:  Eye (Lond)       Date:  1998       Impact factor: 3.775

3.  Quality of life among patients with glaucoma in Sweden.

Authors:  P E Wändell; M Lundström; B Brorsson; H Aberg
Journal:  Acta Ophthalmol Scand       Date:  1997-10

4.  The impact of blurred vision on functioning and well-being.

Authors:  P P Lee; K Spritzer; R D Hays
Journal:  Ophthalmology       Date:  1997-03       Impact factor: 12.079

Review 5.  Recommended stardard procedures for the clinical measurement and specification of visual acuity. Report of working group 39. Committee on vision. Assembly of Behavioral and Social Sciences, National Research Council, National Academy of Sciences, Washington, D.C.

Authors: 
Journal:  Adv Ophthalmol       Date:  1980

6.  Health-related quality of life after elective surgery: measurement of longitudinal changes.

Authors:  C M Mangione; L Goldman; E J Orav; E R Marcantonio; A Pedan; L E Ludwig; M C Donaldson; D J Sugarbaker; R Poss; T H Lee
Journal:  J Gen Intern Med       Date:  1997-11       Impact factor: 5.128

7.  Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients.

Authors:  C L Shields; J A Shields; J Cater; K Gündüz; C Miyamoto; B Micaily; L W Brady
Journal:  Arch Ophthalmol       Date:  2000-09

8.  Correlation of the vision-related functional impairment associated with blepharoptosis and the impact of blepharoptosis surgery.

Authors:  T J Federici; D R Meyer; L L Lininger
Journal:  Ophthalmology       Date:  1999-09       Impact factor: 12.079

9.  Functional status and quality of life measurement among ophthalmic patients.

Authors:  I U Scott; O D Schein; S West; K Bandeen-Roche; C Enger; M F Folstein
Journal:  Arch Ophthalmol       Date:  1994-03

10.  Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology.

Authors: 
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

View more
  6 in total

1.  Two-year patient-reported outcomes following treatment of uveal melanoma.

Authors:  L Hope-Stone; S L Brown; H Heimann; B Damato; P Salmon
Journal:  Eye (Lond)       Date:  2016-09-02       Impact factor: 3.775

2.  [Quality of life - methodology and clinical practice aspects with a focus on ocular medicine].

Authors:  G H Franke; C Gall
Journal:  Ophthalmologe       Date:  2008-08       Impact factor: 1.059

3.  Quality of life and cancer-related needs in patients with choroidal melanoma.

Authors:  Joshua F Wiley; Kelsey Laird; Tammy Beran; Tara A McCannel; Annette L Stanton
Journal:  Br J Ophthalmol       Date:  2013-09-13       Impact factor: 4.638

4.  Health profiles of 996 melanoma survivors: the M. D. Anderson experience.

Authors:  Charles Stava; Martha Beck; L Todd Weiss; Adriana Lopez; Rena Vassilopoulou-Sellin
Journal:  BMC Cancer       Date:  2006-04-18       Impact factor: 4.430

Review 5.  Quality of Life, Depression, and Anxiety in Patients with Uveal Melanoma: A Review.

Authors:  Mario Miniati; Maria Grazia Fabrini; Federica Genovesi Ebert; Maricia Mancino; Alessandra Maglio; Gabriele Massimetti; Enrico Massimetti; Donatella Marazziti
Journal:  J Oncol       Date:  2018-03-20       Impact factor: 4.375

6.  Disability, psychological distress and quality of life in relation to cancer diagnosis and cancer type: population-based Australian study of 22,505 cancer survivors and 244,000 people without cancer.

Authors:  Grace Joshy; Joanne Thandrayen; Bogda Koczwara; Phyllis Butow; Rebekah Laidsaar-Powell; Nicole Rankin; Karen Canfell; John Stubbs; Paul Grogan; Louise Bailey; Amelia Yazidjoglou; Emily Banks
Journal:  BMC Med       Date:  2020-12-01       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.